Previous 10 |
(Source: Evil Speculator) Anyone thinking 2018 investing hasn’t been anything other than a proverbial roller-coaster ride needs their sanity checked. Thankfully, the end of the year is fast approaching, and if given the option to choose - bull or bear - I would have, and did, opt for ...
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 57 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is a...
THE WOODLANDS, Texas, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, will present at the following conference: Stifel ...
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2018 Earnings Conference Call November 1, 2018, 08:00 ET Executives Kimberly Lee - Head, IR & Corporate Strategy Lonnel Coats - President, CEO & Director Pablo Lapuerta - EVP & Chief Medical Officer Jeffrey Wade - EVP, Corpora...
Lexicon Pharmaceuticals (NASDAQ: LXRX ): Q3 GAAP EPS of -$0.26 beats by $0.07 . More news on: Lexicon Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
THE WOODLANDS, Texas, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended September 30, 2018. “In the third quarter, we and our collaborator, Sanofi, have bee...
AAON , AAWW , ABMD , AGIO , ALE , AMAG , AMCX , AME , AMRN , ARES , AROC , ARW , AVP , AYR , BCE , BID , BLL , BMCH , BSIG , CBRE , CCOI , CEIX , CHD , CHSP , CI , CJ , CNQ , CNSL , CWT , D , DM , DNOW , DWDP , EEX , EGRX , EPAM , EXC , EXLS , FLWS , F...
THE WOODLANDS, Texas, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2018 financial results on Thursday, November 1, 2018 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:0...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
INPEFA ® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway with PDUFA Goal Date of December 20, 2024 Commenced SONATA Phase 3 Study...
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...